Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 6/20 | 0.48 |
| ▸ | SPHK1 | Q9NYA1 | 6/20 | 0.47 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.46 |
| ▸ | S1PR1 | P21453 | 6/20 | 0.43 |
| ▸ | S1PR3 | Q99500 | 6/20 | 0.43 |
| ▸ | S1PR4 | O95977 | 4/20 | 0.43 |
| ▸ | S1PR5 | Q9H228 | 4/20 | 0.43 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.43 |
| ▸ | ANPEP | P15144 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21208111 | 0.88 | LTA4H (0.47) | LTA4HSPHK1SPHK2S1PR1S1PR3 | |
| SCHEMBL16645072 | 0.88 | LTA4H (0.47) | LTA4HSPHK1SPHK2S1PR1S1PR3 | |
| SCHEMBL21849119 | 0.88 | LTA4H (0.47) | LTA4HSPHK1SPHK2S1PR1S1PR3 | |
| SCHEMBL19155027 | 0.88 | LTA4H (0.48) | LTA4HSPHK1SPHK2S1PR1S1PR3 | |
| SCHEMBL25100491 | 0.87 | LTA4H (0.46) | LTA4HSPHK1SPHK2S1PR1S1PR3 | |
| SCHEMBL16791610 | 0.86 | ANPEP (0.48) | LTA4HSPHK1SPHK2S1PR1S1PR3 | |
| SCHEMBL19234501 | 0.86 | SPHK1 (0.53) | LTA4HSPHK1SPHK2S1PR1S1PR3 | |
| SCHEMBL20844980 | 0.86 | LTA4H (0.47) | LTA4HSPHK1SPHK2S1PR1S1PR3 | |
| SCHEMBL21208104 | 0.85 | ANPEP (0.48) | LTA4HSPHK1SPHK2S1PR1S1PR3 | |
| SCHEMBL17801791 | 0.85 | SPHK1 (0.51) | LTA4HSPHK1SPHK2S1PR1S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160022833-A1 | SOLID PHASE TGASE-MEDIATED CONJUGATION OF ANTIBODIES | ARARIS BIOTECH LTD (CH) | 2016-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160022833-A1 | SOLID PHASE TGASE-MEDIATED CONJUGATION OF ANTIBODIES | TGM2, TGM3, TGM6 | LTA4H 1656/4885SPHK1 4814/4885SPHK2 4848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.